Related Experiment Videos
NovoSeven in warfarin-treated patients
E Berntorp1, L Stigendal, S Lethagen
1Department for Coagulation Disorders, Lund University, University Hospital, Malmö, Sweden. rik.berntorp@medforsk.mas.lu.se
Summary
Severe bleeding from vitamin K antagonist treatment requires rapid International Normalized Ratio reduction. Recombinant activated factor VII (rFVIIa) showed immediate hemostatic effect in a warfarin-induced nosebleed case, normalizing the INR value.
Area of Science:
- Hematology
- Pharmacology
Background:
- Vitamin K antagonists (VKAs) are crucial anticoagulants but pose a risk of severe hemorrhages.
- Managing elevated International Normalized Ratio (INR) values during bleeding is critical for hemostasis.
- Conventional treatments like plasma carry risks of pathogen transmission.
Observation:
- A pilot trial investigated recombinant activated factor VII (rFVIIa) for VKA-related bleeding.
- rFVIIa, also known as NovoSeven, was administered to patients experiencing bleeding episodes.
- One patient with a warfarin-induced nosebleed was treated with rFVIIa.
Findings:
- The administration of rFVIIa resulted in an immediate hemostatic effect.
- The patient's International Normalized Ratio (INR) value was observed to normalize rapidly after rFVIIa treatment.
- This suggests rFVIIa's potential efficacy in reversing VKA effects during acute bleeding.
Implications:
- rFVIIa may offer a safer and faster alternative to conventional treatments for VKA-associated hemorrhages.
- Further research is warranted to establish the safety and efficacy of rFVIIa in a broader patient population.
- This approach could significantly improve outcomes for patients experiencing life-threatening bleeding while on VKA therapy.